News Center
News Center
No need to travel all the way to Japan! Lenoxacin has been launched at Shulan (Boao) Hospital, and kidney patients can book an assessment online.

      Patients with chronic kidney disease face multiple challenges, including toxin buildup, arteriosclerosis, anemia, and fatigue. Conventional treatments often target only the kidneys themselves, neglecting the interconnected impact of liver detoxification on kidney function.

      Laenec, a human placental extract injection originating from Japan and with over 50 years of clinical application, has officially launched at Shulan (Boao) Hospital, leveraging the special medical policy of Boao Lecheng. This provides a new synergistic liver and kidney management solution for patients with kidney disease and other chronic illnesses. No need to travel abroad; a doctor's consultation and evaluation can be booked with a single click through this WeChat official account.

      I. What is Laenec? A Compliant Imported and Licensed Preparation

      Laenec is an original prescription preparation developed by JBP Corporation of Japan and is also a liver function improvement drug covered by Japanese health insurance. It officially launched at Shulan (Boao) Hospital in September 2024.

      Core Ingredients: Deeply hydrolyzed extract of healthy placenta, containing HGF (hepatocyte growth factor), 8000+ active peptides, amino acids, and cell repair factors; processed with high-temperature inactivation throughout, free of exogenous estrogen; suitable for individuals with a history of breast or gynecological conditions after physician evaluation.

      Core Approved Indications: Improves chronic liver disease and repairs damaged liver cells.

      Compliance Statement: Only designated medical institutions in Boao Lecheng Hospital are permitted to use this product. Online purchases and private distribution are not compliant. Our hospital maintains full traceability through bonded warehouses, and our treatment procedures are standardized.

    image.png

      II. Four Auxiliary Therapy Benefits for Individuals with Chronic Kidney Disease

      Many kidney patients only focus on protecting their kidneys but neglect: The liver is the body's largest detoxification organ; a decline in liver metabolism means toxins will continuously increase the burden on the kidneys. Laennec achieves synergistic liver protection and kidney repair through a dual-channel approach:

      1. Reduces kidney detoxification burden and alleviates systemic discomfort associated with uremia.

      Activates liver cell regeneration, improves liver metabolic efficiency, and reduces the production of urea and guanidine uremic toxins; significantly reduces the continuous filtration load on the kidneys, improving symptoms of toxin accumulation such as nausea, itchy skin, urinary odor in the mouth, and chronic fatigue.

      2. Repairs renal microcirculation, delays renal fibrosis, and stabilizes renal hypertension.

      Repairs the endothelium of microvessels throughout the body, alleviates glomerular hyperperfusion and hyperfiltration, and helps stabilize blood pressure; downregulates pro-fibrotic factors such as TGF-β1 and interleukin-1, reducing renal interstitial fibrosis accumulation, delaying renal tubular atrophy and glomerular sclerosis, and can be used in conjunction with renal shockwave therapy.

      3. Improve Two Typical Complications of Kidney Disease

      * Renal Anemia: Optimizes the systemic hematopoietic microenvironment, synergistically enhances erythropoietin effects, improving pale complexion, shortness of breath, and fatigue.

      * Renal Osteopathy: Regulates calcium and phosphorus metabolism disorders, alleviating bone pain and osteoporosis discomfort.

      4. Antioxidant and Anti-inflammatory, Breaking the Vicious Cycle of Kidney Damage

      Clears excess free radicals in the body, reduces apoptosis of intrinsic renal cells, lowers systemic chronic inflammation levels, slows the decline in renal function, helps prolong dialysis intervals, and delays progression to end-stage renal disease.

      III. Suitable Population for Assessment

      * 1. Individuals with chronic kidney disease (CKD) stages 1-4, diabetic nephropathy, or renal hypertension;

      * 2. Kidney patients on long-term medication, with heavy liver and kidney metabolic burden, frequent fatigue, and itchy skin;

      * 3. Patients with fatty liver, chronic liver damage, or simultaneous liver and kidney damage;

      * 4. Individuals with complications such as renal anemia, bone pain, and endocrine disorders.

      IV. Advantages of Treatment

      ✅ Based at the top-tier Shulan (Boao) Hospital, with legitimate and authorized medical channels and full traceability of medications;

      ✅ Online preliminary screening available, eliminating long queues upon arrival;

      ✅ Personalized kidney protection plans can be customized in conjunction with non-invasive kidney shockwave therapy, intestinal conditioning, and other programs.


Herun International Medical Center, Herun International Preventive Medicine Center, Herun Medical